title: TNFalpha and INFgamma inducing capacity of sera from patients with interstitial lung disease in relation to its angiogenesis activity.
abstract: Sera from interstitial lung diseases (ILD) constitute a source of mediators participating in angiogenesis. The nature of these mediators is unknown. The aim of our study was to asses whether preincubation with sera from ILD patients could influence TNFalpha and INFgamma production by normal mononuclear cells (MNC) challenged with LPS (for TNFalpha) or PHA (for INFgamma), and to correlate the cytokine levels with angiogenic properties of sera. The study population consisted of 53 patients with ILD, 16 with sarcoidosis (SAR), 11 with avian fanciers' lung (AFL), 10 with scleroderma with pulmonary manifestations (SCL), 9 with Wegener's granulomatosis (WG), and 7 with pulmonary Langerhans' cell histiocytosis (PLH). As a control, sera from 10 healthy volunteers were used. Neovascularization was measured by a leukocyte-induced angiogenesis assay according to Sidky and Auerbach. TNFalpha and INFgamma production was estimated by a one-step culture immunoassay CytoTraptrade mark TNFalpha DIA (Biosource Europe S.A.) after 3 h of incubation with LPS (TNFalpha) and 24 h incubation with PHA (INFgamma). Sera from sarcoidosis patients, WG patients, and AFL patients significantly stimulated angiogenesis in comparison with sera from healthy donors (P<0.001). Sera from PLH and SCL patients presented anti-angiogenic properties in comparison with sera from healthy donors and from each examined group (P<0.001). Comparing with other groups, preincubation with sera from AFL and WG patients led to a significant increase in TNFalpha production by normal MNC. Highly significant correlation between serum angiogenic activity and TNFalpha production by MNC was observed in SCL, WG, and AFL (r=0.74, P<0.01). we conclude that TNFalpha may play an important role in neovascularization in ILD.
authors.affiliation: Department of Family Medicine, Warsaw Medical University, Warsaw, Poland. tmzielonka@wp.pl
authors.forename: T M
authors.initials: TM
authors.lastname: Zielonka
authors.forename: U
authors.initials: U
authors.lastname: Demkow
authors.forename: E
authors.initials: E
authors.lastname: Puscinska
authors.forename: A
authors.initials: A
authors.lastname: Golian-Geremek
authors.forename: M
authors.initials: M
authors.lastname: Filewska
authors.forename: K
authors.initials: K
authors.lastname: Zycinska
authors.forename: B
authors.initials: B
authors.lastname: Białas-Chromiec
authors.forename: K A
authors.initials: KA
authors.lastname: Wardyn
authors.forename: E
authors.initials: E
authors.lastname: Skopińska-Rózewska
mesh_terms: D000328:Adult; D000368:Aged; D000818:Animals; D005260:Female; D014890:Granulomatosis with Polyangiitis / Q000097:blood; D006801:Humans; D007371:Interferon-gamma / Q000096:biosynthesis*; D008070:Lipopolysaccharides / Q000494:pharmacology; D017563:Lung Diseases, Interstitial / Q000097:blood*; D008297:Male; D051379:Mice; D008875:Middle Aged; D009000:Monocytes / Q000187:drug effects / Q000378:metabolism; D009389:Neovascularization, Pathologic / Q000473:pathology*; D010835:Phytohemagglutinins / Q000494:pharmacology; D012507:Sarcoidosis / Q000097:blood; D012595:Scleroderma, Systemic / Q000097:blood; D012907:Smoking / Q000473:pathology; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis*
chemical_list: D008070:Lipopolysaccharides; D010835:Phytohemagglutinins; D014409:Tumor Necrosis Factor-alpha; D007371:Interferon-gamma